Journal article

Status of PCSK9 Monoclonal Antibodies in Australia

Daniel J Scherer, Adam J Nelson, Richard O'Brien, Karam M Kostner, David L Hare, David M Colquhoun, Philip J Barter, Philip Aylward, Stephen J Nicholls, Gerald F Watts

Heart, Lung and Circulation | ELSEVIER SCIENCE INC | Published : 2019

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analys..

View full abstract